# Lifecode

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lifecode

- Industry: Biotechnology
- Headquarters: Foster City, US
- Website: www.lifecodehealth.com
- Total disclosed funding: $22M
- Latest round: Series A (Feb 19, 2015)
- Investors on record: 3

## About

Lifecode, Inc. is a biotechnology firm focused on molecular tumor profiling using advanced sequencing technology to provide comprehensive genomic analysis, aiding personalized cancer treatment decisions for patients and healthcare providers.Founded in 2012 in Foster City, US, Lifecode, Inc. specializes in molecular tumor profiling. The company has undertaken four investment rounds, with the latest being a Series A round on February 19, 2015, where it raised USD 20.5 mn from investors including Mayo Clinic, Mayo Clinic Ventures, and Sequoia Capital. The company's founders include Slobodan Obrenovic and Yvonne Davenport-Perkins, with Fernando Assunção serving as the CEO.Life Code Health specializes in molecular tumor profiling through advanced next-generation sequencing (NGS) technology. Their services focus on comprehensive genomic analysis and therapeutic data interpretation, facilitating personalized treatment decisions for cancer patients. They cater to a variety of clients, including healthcare providers and research institutions, predominantly in the United States, with aspirations for international market expansion.Life Code Health generates revenue through direct service offerings and collaborations with healthcare software development companies. Their clinical laboratory provides molecular profiling tests integral to transactions with healthcare providers and research institutions, typically structured as fee-for-service arrangements. The company maintains a pricing structure designed for competitiveness while ensuring high-quality testing.Looking ahead, Lifecode, Inc. plans to utilize the USD 20.5 mn raised in their latest Series A financing to enhance their product offerings and expand into new geographic markets. Specific initiatives include the development of new molecular profiling products aimed at improving patient care. The company aims to enter additional international markets, leveraging its established technology and expertise by 2025, thus supporting its growth trajectory.

## Funding rounds

- Series A, Feb 19, 2015, $21M — Mayo Clinic Ventures, Hong Shan, Mayo Clinic
- Series A, Aug 12, 2011, $1M — Hong Shan

## Investors

- Hong Shan — Series A
- Mayo Clinic Ventures (https://capitalatlas.ai/funds/mayo-clinic-ventures) — Series A
- Mayo Clinic — Series A